Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Panblok H7 Vaccine with AS03 or MF59 Adjuvants
NCT03283319Phase 2Completed
- Sponsor
- Biomedical Advanced Research and Development Authority
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Panblok H7, sponsored by Biomedical Advanced Research and Development Authority. Started Sep 2017; status: completed.
02
Drugs
Panblok H7
Beyond the preview
Go deeper on NCT03283319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283319.